JP2005515192A - ヒト又は動物において免疫応答を誘導するための医薬組成物 - Google Patents
ヒト又は動物において免疫応答を誘導するための医薬組成物 Download PDFInfo
- Publication number
- JP2005515192A JP2005515192A JP2003546928A JP2003546928A JP2005515192A JP 2005515192 A JP2005515192 A JP 2005515192A JP 2003546928 A JP2003546928 A JP 2003546928A JP 2003546928 A JP2003546928 A JP 2003546928A JP 2005515192 A JP2005515192 A JP 2005515192A
- Authority
- JP
- Japan
- Prior art keywords
- mage
- cancer
- dendritic cells
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 51
- 230000028993 immune response Effects 0.000 title claims abstract description 38
- 241001465754 Metazoa Species 0.000 title claims abstract description 37
- 230000001939 inductive effect Effects 0.000 title claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 315
- 108091007433 antigens Proteins 0.000 claims abstract description 314
- 102000036639 antigens Human genes 0.000 claims abstract description 314
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 209
- 201000011510 cancer Diseases 0.000 claims abstract description 157
- 230000004069 differentiation Effects 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 81
- 210000001550 testis Anatomy 0.000 claims abstract description 76
- 210000004027 cell Anatomy 0.000 claims description 259
- 210000004443 dendritic cell Anatomy 0.000 claims description 195
- 201000001441 melanoma Diseases 0.000 claims description 89
- 230000014509 gene expression Effects 0.000 claims description 84
- 239000002609 medium Substances 0.000 claims description 56
- 102000004127 Cytokines Human genes 0.000 claims description 46
- 108090000695 Cytokines Proteins 0.000 claims description 46
- 210000001616 monocyte Anatomy 0.000 claims description 44
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 43
- 210000002752 melanocyte Anatomy 0.000 claims description 38
- 230000012010 growth Effects 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 23
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 230000009089 cytolysis Effects 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 21
- 102000004388 Interleukin-4 Human genes 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 20
- 108090000978 Interleukin-4 Proteins 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 18
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 18
- 238000011068 loading method Methods 0.000 claims description 18
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 17
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 108010074328 Interferon-gamma Proteins 0.000 claims description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 15
- 102100037850 Interferon gamma Human genes 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- -1 MAGE- C4 Proteins 0.000 claims description 13
- 239000012130 whole-cell lysate Substances 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 12
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 10
- 230000017858 demethylation Effects 0.000 claims description 9
- 238000010520 demethylation reaction Methods 0.000 claims description 9
- 102000003425 Tyrosinase Human genes 0.000 claims description 8
- 108060008724 Tyrosinase Proteins 0.000 claims description 8
- 230000035800 maturation Effects 0.000 claims description 8
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 7
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 7
- 102100035793 CD83 antigen Human genes 0.000 claims description 7
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 7
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 claims description 7
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 claims description 7
- 101001114052 Homo sapiens P antigen family member 4 Proteins 0.000 claims description 7
- 102100040578 G antigen 7 Human genes 0.000 claims description 6
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims description 6
- 102100023240 P antigen family member 4 Human genes 0.000 claims description 6
- 210000001808 exosome Anatomy 0.000 claims description 6
- 102100039717 G antigen 1 Human genes 0.000 claims description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims description 5
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 claims description 5
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 claims description 4
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 claims description 4
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 claims description 4
- 101001036689 Homo sapiens Melanoma-associated antigen B5 Proteins 0.000 claims description 4
- 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 claims description 4
- 101000825248 Homo sapiens Sperm protein associated with the nucleus on the X chromosome C Proteins 0.000 claims description 4
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 claims description 4
- 101000814497 Homo sapiens X antigen family member 3 Proteins 0.000 claims description 4
- 102000003816 Interleukin-13 Human genes 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102100039475 Melanoma-associated antigen B5 Human genes 0.000 claims description 4
- 102100039483 Melanoma-associated antigen B6 Human genes 0.000 claims description 4
- 102100022322 Sperm protein associated with the nucleus on the X chromosome C Human genes 0.000 claims description 4
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 claims description 4
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 claims description 4
- 102100039490 X antigen family member 1 Human genes 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- WKPZKRWOIZKCDN-WAQYZQTGSA-N ctp-11 Chemical compound Cl.C=1C=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=1OC(=O)N(CC1)CCC1N1CCCCC1 WKPZKRWOIZKCDN-WAQYZQTGSA-N 0.000 claims description 4
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 claims description 4
- 235000002020 sage Nutrition 0.000 claims description 4
- 102100039699 G antigen 4 Human genes 0.000 claims description 3
- 101710092267 G antigen 5 Proteins 0.000 claims description 3
- 102100039698 G antigen 5 Human genes 0.000 claims description 3
- 101710092269 G antigen 6 Proteins 0.000 claims description 3
- 102100039713 G antigen 6 Human genes 0.000 claims description 3
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 claims description 3
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 claims description 3
- 101001114057 Homo sapiens P antigen family member 1 Proteins 0.000 claims description 3
- 101001114053 Homo sapiens P antigen family member 3 Proteins 0.000 claims description 3
- 101000814511 Homo sapiens X antigen family member 2 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102100027248 Melanoma-associated antigen C3 Human genes 0.000 claims description 3
- 102100023239 P antigen family member 3 Human genes 0.000 claims description 3
- 102100039492 X antigen family member 2 Human genes 0.000 claims description 3
- 102100039491 X antigen family member 3 Human genes 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 229960002986 dinoprostone Drugs 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 3
- 230000007910 cell fusion Effects 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 5
- 230000035131 DNA demethylation Effects 0.000 claims 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 48
- 102000004169 proteins and genes Human genes 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 210000004698 lymphocyte Anatomy 0.000 description 21
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 18
- 239000006166 lysate Substances 0.000 description 16
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 15
- 210000005087 mononuclear cell Anatomy 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 238000009169 immunotherapy Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000000242 pagocytic effect Effects 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 10
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002121 endocytic effect Effects 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 8
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000012737 microarray-based gene expression Methods 0.000 description 8
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002101 lytic effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 229940032219 immunotherapy vaccine Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101100170001 Caenorhabditis elegans ddb-1 gene Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 239000012650 DNA demethylating agent Substances 0.000 description 2
- 229940045805 DNA demethylating agent Drugs 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102000016200 MART-1 Antigen Human genes 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000013967 Monokines Human genes 0.000 description 2
- 108010050619 Monokines Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 102100021466 Sarcoma antigen 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940115256 melanoma vaccine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108090000749 Aurora kinase B Proteins 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 108010059045 HLA-C*06 antigen Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101001093139 Homo sapiens MAU2 chromatid cohesion factor homolog Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 101001114056 Homo sapiens P antigen family member 2 Proteins 0.000 description 1
- 101000633613 Homo sapiens Probable threonine protease PRSS50 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100036309 MAU2 chromatid cohesion factor homolog Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100023220 P antigen family member 2 Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100029523 Probable threonine protease PRSS50 Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 208000033749 Small cell carcinoma of the bladder Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- GKKDCARASOJPNG-UHFFFAOYSA-N metaldehyde Chemical compound CC1OC(C)OC(C)OC(C)O1 GKKDCARASOJPNG-UHFFFAOYSA-N 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000005949 negative regulation of histone deacetylation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000008759 sweat gland cancer Diseases 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000007710 urinary bladder small cell neuroendocrine carcinoma Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101770 | 2001-11-29 | ||
| US33670601P | 2001-12-07 | 2001-12-07 | |
| PCT/DK2002/000802 WO2003045427A2 (en) | 2001-11-29 | 2002-11-29 | Pharmaceutical composition for inducing an immune response in a human or animal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005515192A true JP2005515192A (ja) | 2005-05-26 |
| JP2005515192A5 JP2005515192A5 (enExample) | 2006-01-05 |
Family
ID=26069102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546928A Pending JP2005515192A (ja) | 2001-11-29 | 2002-11-29 | ヒト又は動物において免疫応答を誘導するための医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7771998B2 (enExample) |
| EP (1) | EP1448229B1 (enExample) |
| JP (1) | JP2005515192A (enExample) |
| AT (1) | ATE446106T1 (enExample) |
| AU (1) | AU2002365291B2 (enExample) |
| DE (1) | DE60234115D1 (enExample) |
| DK (1) | DK1448229T3 (enExample) |
| ES (1) | ES2335396T3 (enExample) |
| IL (1) | IL161832A0 (enExample) |
| RU (1) | RU2313365C2 (enExample) |
| WO (1) | WO2003045427A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009540812A (ja) * | 2006-06-21 | 2009-11-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｍａｇｅ−ａ３マーカーの特異的検出のためのプライマーおよびプローブを含む癌の検出および診断の方法 |
| JP2010515670A (ja) * | 2007-01-08 | 2010-05-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 癌治療のための、手術、化学療法または放射線療法と併用した免疫療法におけるｍａｇｅａ３−プロテインｄ融合抗原の使用 |
| US8283163B2 (en) | 2007-05-17 | 2012-10-09 | Dnavec Corporation | Method for production of dendritic cell |
| JP2013535218A (ja) * | 2010-08-11 | 2013-09-12 | サイトヴァック エイ／エス | 樹状細胞を産生するための組成物及び方法 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
| DE10112851C1 (de) * | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| ES2294346T3 (es) * | 2002-11-28 | 2008-04-01 | Peter Kufer | Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage. |
| DE602005027738D1 (de) * | 2004-11-18 | 2011-06-09 | Univ Hiroshima Nat Univ Corp | Verfahren und kit zur expression von protein unter regulation der expression von einer durch genamplifikation gebildeten wiederholungssequenz und transformant |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| BRPI0706784A2 (pt) | 2006-01-30 | 2011-04-05 | Ludwig Inst Cancer Res | antìgeno de cáncer de testìculo ctsp |
| JP2011529080A (ja) * | 2008-07-24 | 2011-12-01 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド | 癌幹細胞を標的とする治療法 |
| BRPI0920679A2 (pt) * | 2008-10-08 | 2022-05-17 | Intrexon Corp | Células construídas expressando múltiplos imunomoduladores e usos das mesmas |
| WO2011028531A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| MX362513B (es) * | 2010-03-23 | 2019-01-22 | Intrexon Corp | Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos. |
| UA116528C2 (uk) | 2011-08-30 | 2018-04-10 | Астекс Фармасьютікалз, Інк. | Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування |
| CA2852967A1 (en) * | 2011-10-20 | 2013-04-25 | California Stem Cell, Inc. | Antigen presenting cancer vaccine |
| JP5871228B2 (ja) * | 2011-10-31 | 2016-03-01 | 国立大学法人佐賀大学 | 慢性副鼻腔炎の検出方法 |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| WO2014007669A1 (ru) * | 2012-07-04 | 2014-01-09 | Volgushev Sergei Anatolievich | Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения |
| CN108024535A (zh) | 2015-07-02 | 2018-05-11 | 大塚制药株式会社 | 冻干药物组合物 |
| SG10202112047TA (en) | 2015-09-18 | 2021-12-30 | Baylor College Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| GB201520542D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| MX2020001233A (es) | 2017-08-03 | 2020-07-20 | Otsuka Pharma Co Ltd | Compuesto farmaceutico y metodos de purificacion del mismo. |
| KR20210044207A (ko) * | 2018-07-15 | 2021-04-22 | 이노치안 바이오파마, 인코포레이티드 | 암 치료를 위한 재조합 수지상 세포를 사용하는 방법 및 조성물 |
| EP3903811A1 (en) | 2020-05-01 | 2021-11-03 | R.G.C.C. Holdings AG | Pharmaceutical composition and method for inducing an immune response |
| CA3119597C (en) | 2020-10-12 | 2023-07-11 | R.G.C.C. Holdings AG | Sars-cov-2 vaccines |
| EP3981425A1 (en) | 2020-10-12 | 2022-04-13 | R.G.C.C. Holdings AG | Sars-cov-2 vaccines |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| WO2001041787A1 (en) | 1999-12-10 | 2001-06-14 | Epimmune Inc. | INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| US20040241176A1 (en) * | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| AU2002252268B2 (en) | 2001-03-09 | 2007-01-18 | Baylor Research Institute | Method of treating malignancies through induction of blood immune responses |
-
2002
- 2002-11-29 ES ES02803755T patent/ES2335396T3/es not_active Expired - Lifetime
- 2002-11-29 RU RU2004119548/13A patent/RU2313365C2/ru active
- 2002-11-29 AU AU2002365291A patent/AU2002365291B2/en not_active Expired
- 2002-11-29 DK DK02803755.4T patent/DK1448229T3/da active
- 2002-11-29 AT AT02803755T patent/ATE446106T1/de not_active IP Right Cessation
- 2002-11-29 US US10/495,511 patent/US7771998B2/en not_active Expired - Lifetime
- 2002-11-29 EP EP02803755A patent/EP1448229B1/en not_active Expired - Lifetime
- 2002-11-29 IL IL16183202A patent/IL161832A0/xx unknown
- 2002-11-29 DE DE60234115T patent/DE60234115D1/de not_active Expired - Lifetime
- 2002-11-29 JP JP2003546928A patent/JP2005515192A/ja active Pending
- 2002-11-29 WO PCT/DK2002/000802 patent/WO2003045427A2/en not_active Ceased
-
2008
- 2008-07-29 US US12/182,089 patent/US7723107B2/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009540812A (ja) * | 2006-06-21 | 2009-11-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｍａｇｅ−ａ３マーカーの特異的検出のためのプライマーおよびプローブを含む癌の検出および診断の方法 |
| JP2010515670A (ja) * | 2007-01-08 | 2010-05-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 癌治療のための、手術、化学療法または放射線療法と併用した免疫療法におけるｍａｇｅａ３−プロテインｄ融合抗原の使用 |
| US8283163B2 (en) | 2007-05-17 | 2012-10-09 | Dnavec Corporation | Method for production of dendritic cell |
| JP2013535218A (ja) * | 2010-08-11 | 2013-09-12 | サイトヴァック エイ／エス | 樹状細胞を産生するための組成物及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2313365C2 (ru) | 2007-12-27 |
| EP1448229B1 (en) | 2009-10-21 |
| AU2002365291A1 (en) | 2003-06-10 |
| DK1448229T3 (da) | 2010-03-08 |
| WO2003045427A3 (en) | 2004-03-25 |
| US7723107B2 (en) | 2010-05-25 |
| WO2003045427A2 (en) | 2003-06-05 |
| US20060051324A1 (en) | 2006-03-09 |
| RU2004119548A (ru) | 2005-03-27 |
| ATE446106T1 (de) | 2009-11-15 |
| DE60234115D1 (de) | 2009-12-03 |
| IL161832A0 (en) | 2005-11-20 |
| ES2335396T3 (es) | 2010-03-26 |
| HK1086750A1 (zh) | 2006-09-29 |
| AU2002365291B2 (en) | 2007-11-01 |
| US20090029457A1 (en) | 2009-01-29 |
| EP1448229A2 (en) | 2004-08-25 |
| US7771998B2 (en) | 2010-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7723107B2 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| Schuler-Thurner et al. | Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells | |
| Butterfield et al. | Adenovirus MART-1–engineered autologous dendritic cell vaccine for metastatic melanoma | |
| Kawakami et al. | Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. | |
| Märten et al. | Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial | |
| Wu et al. | Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas | |
| EP1412748B1 (en) | Mage-a3 peptides presented by hla class ii molecules | |
| US20170173130A1 (en) | Cancer vaccines and vaccination methods | |
| US20020119121A1 (en) | Compositions and methods for inducing specific cytolytic T cell responses | |
| Gyorffy et al. | Bone marrow‐derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen | |
| US9694059B2 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| CN101861163B (zh) | 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法 | |
| US20140234350A1 (en) | Ovarian cancer vaccines and vaccination methods | |
| US7311914B2 (en) | MAGE-A4 antigenic peptides and uses thereof | |
| Li et al. | MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer | |
| Marchand et al. | Biological and clinical developments in melanoma vaccines | |
| JP2006509830A (ja) | 癌予防用ハイブリッド細胞ワクチンの調製および投与 | |
| CN100558400C (zh) | 诱导人或动物免疫应答的药物组合物 | |
| US20030185808A1 (en) | Prostate cell lines | |
| HK1086750B (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| WO2006015497A1 (en) | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors | |
| Soruri et al. | In vitro generation of cytolytic T cells against human melanoma cells overexpressing HDM2 | |
| Morse et al. | Dendritic cell-based approaches to cancer immunotherapy | |
| Berke et al. | Cytotoxicity Assays: Killer Lymphocytes in Cancer | |
| Minkis | Construction of an optimal immunogen using mRNA transfected dendritic cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051011 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051011 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090602 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090707 |